Agomelatine: a new option for treatment of depression? (Q48375336)

11 February 2018

editorial

0 references

title

Agomelatine: a new option for treatment of depression? (English)

1 reference

11 February 2018

author name string

Chi-Un Pae

series ordinal

1 reference

11 February 2018

language of work or name

English

0 references

publication date

8 January 2014

1 reference

11 February 2018

Expert Opinion on Pharmacotherapy

published in

1 reference

11 February 2018

volume

1 reference

11 February 2018

issue

1 reference

11 February 2018

page(s)

443-447

1 reference

11 February 2018

Triple Reuptake Inhibitors: A Premise and Promise

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Novel melatonin-based therapies: potential advances in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Publication bias and outcome reporting bias: agomelatine as a case example

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

The efficacy of agomelatine in previously-treated depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

A benefit-risk assessment of agomelatine in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Chronobiology of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Manipulating melatonin in managing mood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Getting depression clinical practice guidelines right: time for change?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Neurogenesis along the septo-temporal axis of the hippocampus: are depression and the action of antidepressants region-specific?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

Antidepressant efficacy of agomelatine versus SSRI/SNRI

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.877889

10.1517/14656566.2014.877889

21 January 2018

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018